menu
    • menu
    [{"orgOrder":0,"company":"Vectans Pharma","sponsor":"m8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Miconazole","moa":"CYP50","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vectans Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vectans Pharma \/ m8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Vectans Pharma \/ m8 Pharmaceuticals"},{"orgOrder":0,"company":"Fortovia Therapeutics","sponsor":"Galt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Miconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fortovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fortovia Therapeutics \/ Galt Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Fortovia Therapeutics \/ Galt Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Miconazole

    Menu

    Miconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fortovia Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Fortovia Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Galt Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Galt Pharmaceuticals® Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics

                            Details : Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.

                            Brand Name : Oravig

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 16, 2020

                            Lead Product(s) : Miconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Galt Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vectans Pharma

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Vectans Pharma

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : m8 Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            m8 Pharmaceuticals and Vectans Pharma Enter Agreement

                            Details : m8 Pharmaceuticals and Vectans Pharma have signed an exclusive licensing agreement whereby m8 will have the rights to register and commercialize Loramyc® (miconazole) for Mexico and Brazil.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 18, 2020

                            Lead Product(s) : Miconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : m8 Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth